Moving Beyond JAK Inhibitors in Myeloproliferative Neoplasms
2 Pogledi
• 07/29/23
0
0
Ugraditi
administrator
Pretplatnici
Naveen Pemmaraju, MD, discusses the need to move beyond JAK inhibition when treating patients with myeloproliferative neoplasms.
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari